ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

All Content

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy regimens failed to prolong overall survival in lung and breast cancers.

Mateusz Opyrchal, MD, PhD, talks about his study on the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.

Using state-of-the-art gene editing technology, researchers have discovered a promising target to treat atypical teratoid/rhabdoid tumor (AT/RT), a highly aggressive and therapy-resistant brain tumor.

In this video, Michael Ciesielski, PhD, of Roswell Park Cancer Institute in Buffalo, talks about circulating exosomes isolated from the serum of malignant glioma patients enrolled in a completed phase I clinical trial of an anti-survivin vaccine (SurVaxM).

A 27-year-old African American man presents with a soft tissue lesion in his right chest. After a biopsy is performed, what is your diagnosis?

Kinase oncoproteins and growth factors both activate the proto-oncogene c-FOS and DUSP1, allowing the persistence of residual leukemia cell populations despite tyrosine kinase inhibitor therapy.

In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.

Dr. Heather Wakelee discusses the management of lung cancer patients who have early or delayed progression while being treated with an immune checkpoint inhibitor.

Patients with mucosa-associated lymphoid tissue (MALT) lymphoma had improved event-free survival when treated with chlorambucil plus rituximab compared with either therapy alone.

Unmutated immunoglobulin heavy chain variable region gene (IGHV) status does not adversely impact survival among ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.